This is a preview of subscription content, log in via an institution to check access.
Reference
Vertex Pharmaceuticals Incorporated. Republic of Ireland Approves Funding for KALYDECO (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis, for People with a Specific Genetic Mutation (G551D). Media Release : 1 Feb 2013. Available from: URL: http://www.vrtx.com
Rights and permissions
About this article
Cite this article
Ivacaftor funded in Ireland. PharmacoEcon Outcomes News 671, 11 (2013). https://doi.org/10.1007/s40274-013-0152-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0152-9